<DOC>
	<DOCNO>NCT00719550</DOCNO>
	<brief_summary>Study Phase : 1b/2 Indication : Previously untreated subject unresectable locally advanced metastatic gastric esophagogastric junction adenocarcinoma . Primary Objective ( ) : Part 1 : To identify safe dose level AMG 102 , 15 mg/kg Q3W , combine ECX . Part 2 ( phase 2-double-blind ) : To estimate pre-specified precision effect addition AMG 102 ECX progression free survival ( PFS ) .</brief_summary>
	<brief_title>AMG 102 Plus ECX Unresectable Locally Advanced Metastatic Gastric Esophagogastric Junction Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Pathologically confirm unresectable locally advanced metastatic gastric esophagogastric junction ( EGJ ) adenocarcinoma ; tumor distal esophagus within 5 cm EGJ eligible ECOG performance status 0 1 Male female ≥ 18 year age Previous systemic therapy ( chemotherapy biologic therapy ) locally advanced metastatic gastric esophagogastric adenocarcinoma Less 6 month elapse completion prior neoadjuvant adjuvant chemotherapy chemoradiotherapy . Subjects resectable disease suitable definitive chemoradiation Subjects persistent gastric outlet obstruction , complete dysphagia feed jejunostomy Tumors squamous cell histology Known central nervous system metastases Clinically significant upper gastrointestinal bleeding ≤ 30 day prior enrollment randomization Serious nonhealing wound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Locally Advanced</keyword>
	<keyword>Metastatic</keyword>
</DOC>